What Lartruvo Treats: Main Uses and Benefits

Lartruvo (Olaratumab) is applied in the therapeutic domain of Oncology for the systemic treatment of Soft Tissue Sarcoma (STS) that has reached an advanced stage. The therapy is relevant in situations where curative local methods, such as surgery or radiation, are no longer appropriate. It is specifically used in combination with doxorubicin as the first-line treatment for adult patients who are anthracycline-naïve for their advanced disease, and is applied across conditions presenting with systemic or localized discomfort.

---

This medication is applied as part of the initial systemic treatment of advanced STS. It is utilized exclusively in combination with the chemotherapy agent doxorubicin for adult patients who are anthracycline-naïve for their advanced disease. This combination approach is relevant for conditions associated with acute or disruptive episodes, assisting with the management of symptoms related to heightened physiological activity, and may assist with managing symptoms that interfere with daily functioning. The use of this combination helps maintain a sense of stability when symptoms are more noticeable and supports general well-being during symptomatic phases.

“The approach is relevant in contexts involving heightened systemic burden, helping to ease the overall symptom burden.”

Quick Fact: Support for Advanced Disease Burden

Lartruvo is commonly used to help with conditions presenting with systemic or localized discomfort and is relevant for managing symptom clusters that may become intense or disruptive, supports patients during episodes of heightened discomfort.

Eligibility Map: Who can and cannot use Lartruvo — Official Regulatory Information

The official eligibility profile for Lartruvo is defined by current regulatory advice and specific patient population requirements.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult patients (18 years and older). Current patients who are determined to be receiving clinical benefit may continue treatment.
Populations for whom use is not recommended	New patients should not initiate Lartruvo therapy outside of an investigational study. Breastfeeding women are not recommended to use Lartruvo during treatment and for 3 months afterward.
Populations for whom use is contraindicated	Patients with known hypersensitivity to olaratumab or its formulation. Permanent discontinuation is required after experiencing a Grade 3 or 4 infusion-related reaction.
Age-related eligibility rules	Use is not established in the pediatric population (under 18 years). Use is authorized for adults.
Condition-specific eligibility rules	Use is unknown in patients with severe renal impairment or severe hepatic impairment.
Pregnancy and lactation eligibility status	Pregnancy: Use should be avoided as Lartruvo can cause fetal harm. Females of reproductive potential must use effective contraception during treatment and for 3 months after the final dose.

---

Eligibility Classifications (High-Level)

Category	Classification Details
Eligibility severity classification	Contraindicated (Hypersensitivity, Grade 3/4 IRR); Not Recommended (New Patient Initiation, Breastfeeding); Not Established (Pediatric Use, Severe Organ Impairment).
Regulatory basis	The conditional approval status was re-evaluated, leading to official recommendations against initiating treatment in new patients.

---

Connection to the overall eligibility profile

The official profile is defined primarily by the regulatory recommendation against initiation in new patients, reflecting the re-evaluation of the medicine’s conditional approval status. Consequently, use is restricted to adult patients who were already on treatment and are receiving documented benefit, while use is prohibited for new patients, pregnant women, and those who experience severe infusion reactions.

Interaction Map: Interactions with other medicines and products — official regulatory information for Lartruvo

Category	Official Regulatory Statement
Pharmacokinetic Interactions	No clinically relevant changes in patient exposure to Olaratumab or doxorubicin were observed when co-administered [FDA Label]. As a monoclonal antibody, Olaratumab is cleared by catabolism and is not anticipated to affect or be affected by Cytochrome P450 (CYP) enzymes [EMA SmPC].
Pharmacodynamic Interactions	Co-administration with doxorubicin is associated with a documented increased incidence and severity of certain adverse events, including neutropenia and haemorrhagic events [EMA SmPC].
Physical/Timing Restrictions	The Olaratumab solution must not be co-infused with electrolytes or other medications through the same intravenous line due to physical incompatibility constraints [FDA Label, EMA SmPC].
Other Substances	No formal drug interaction studies have been performed with many common concomitant medicines (e.g., antiemetics) [EMA SmPC]. Interactions with food or herbal products have not been established in regulatory documentation.
Population-Specific Notes	The clinical effects of severe renal impairment or severe hepatic impairment on Olaratumab exposure are officially designated as unknown in the prescribing information [FDA Label].

Connection to the overall interaction profile: The regulatory profile establishes that the large-molecule structure of Olaratumab results in the absence of conventional pharmacokinetic interactions with its co-therapy, doxorubicin. However, a pharmacodynamic interaction is documented, requiring monitoring for heightened toxicity risks during combination use. Regulatory labeling also imposes a strict physical administration rule prohibiting co-infusion with other substances via the same intravenous line to ensure solution integrity.

Targeted Blockade of Pro-Survival Signaling

Lartruvo (Olaratumab) is a monoclonal antibody engineered to bind to the Platelet-derived growth factor receptor alpha (PDGFR-alpha) on the exterior of targeted cells. By physically blocking the receptor, the drug prevents natural growth factors from attaching, which effectively shuts down the entire internal signal transduction cascade responsible for sending signaling sequences that drive cellular proliferation and survival.

Interference with the Tumor Support Microenvironment

The drug's mechanism extends beyond tumor cells to affect PDGFR-alpha receptors on supporting cells in the surrounding microenvironment. This action disrupts the paracrine signaling involved in supporting the proliferation of the tumor, thereby reducing the influence of factors that promote cell proliferation. This targeted inhibition may increase the susceptibility of cells to non-selective mechanisms, such as those of co-administered chemotherapy like Doxorubicin.

Physiological Consequence: Suppression of Proliferation

The suppression of the PDGFR-alpha pathway and the disruption of the supportive cellular network results in the physiological consequence of reduced cell proliferation and viability. While the functional effect of the mechanism can be subject to biological limitations, such as compensatory signaling pathways, its targeted interruption of a fundamental growth cascade is the basis for the resulting physiological consequence.

How Lartruvo is Used: Official Administration Guidelines

Lartruvo (olaratumab) is administered according to a specific, standardized protocol. Its use is defined by the administration route, a body-weight calculated dose, and a precise treatment schedule, as detailed in the official prescribing information.

---

Official Administration Protocol

Administration Scope	Details
Route of Administration	Exclusively via intravenous (IV) infusion. It must not be given as an IV push or bolus.
Dosing Schedule	The standard dose is 15 mg per kilogram of the patient's body weight.
Frequency and Timing	Administered on Day 1 and Day 8 of a fixed 21-day cycle. Each infusion typically lasts approximately 60 minutes.
Duration Pattern	Used in combination therapy with doxorubicin for the initial 8 cycles, followed by continuation as monotherapy until disease progression.

---

Preparation and Procedural Rules

The Lartruvo concentrate must be diluted prior to administration to a final volume of 250 mL using 0.9% Sodium Chloride Injection, USP; dextrose-containing solutions must not be used. Premedication is required before the first infusion in Cycle 1. For instances of a missed dose, the infusion should be given as soon as possible, provided it is not scheduled on the same day as the next planned dose, thereby maintaining the established 21-day cycle schedule. No specific dose adjustments are provided in the label for mild-to-moderate baseline renal or hepatic impairment.

Research Evidence / Overview of Studies for Lartruvo

---

Evidence for Use in Advanced Soft Tissue Sarcoma (STS)

The research basis for Lartruvo (olaratumab) was studied for adult patients with advanced or metastatic soft tissue sarcoma (STS) who had not previously received a type of chemotherapy called anthracycline. The initial clinical evidence was evaluated in a smaller, randomized Phase 2 trial which compared Lartruvo in combination with doxorubicin against doxorubicin alone. This study specifically measured key clinical outcomes, including Overall Survival (OS) and Progression-Free Survival (PFS). Findings describe patterns observed in the small study population, and data showed a difference in the median survival measurements, which were longer in the combination group compared to doxorubicin alone. The initial Phase 2 research was associated with the conditional regulatory authorization granted by agencies like the FDA and EMA.

---

Conflicting Findings in the Confirmatory Research

Following conditional authorization, a larger, global, randomized, double-blind, placebo-controlled Phase 3 trial, known as the ANNOUNCE study, was required by regulators to confirm the evidence. This research examined the same primary outcomes, including Overall Survival, in a larger patient group.

However, the definitive Phase 3 trial did not describe a statistically significant difference in the measurements of Overall Survival when comparing the Lartruvo combination to doxorubicin plus placebo. Research highlights that this later trial did not meet its primary objective to confirm the patterns of extended survival seen in the earlier, smaller study. Findings were mixed, and the overall evidence was considered inconsistent when comparing the initial data to the final, large-scale controlled data.

---

What Remains Uncertain About the Research Record

The most significant limitation in the research is the inconsistency between the initial findings from the small Phase 2 study and the results of the larger, more robust Phase 3 trial. The initial evidence was considered limited and was not verified by the confirmatory data. As a direct consequence of the Phase 3 trial not meeting its primary objective, regulatory bodies determined that the previously observed clinical benefit was not confirmed, leading to the withdrawal of the medicine's marketing authorization.

Common questions about Lartruvo (FAQ)

Q: Why was Lartruvo's approval status later changed by the FDA?

Lartruvo was initially granted accelerated approval, which required a large, confirmatory study (the ANNOUNCE trial) to verify its clinical benefit. Official regulatory documents indicate that the approval was later withdrawn because the confirmatory study did not confirm the original finding of extended patient survival. This meant the clinical benefit initially observed was not verified in the final, controlled trial.

Q: Are there specific vitamins, supplements, or herbal products that interact with Lartruvo?

The official regulatory labeling for Lartruvo does not formally list or establish known interactions with common vitamins, supplements, or herbal products. This lack of formal study means specific warnings are not provided in the prescribing information. Regulatory guidance recommends informing a healthcare provider about all products being used.

Q: What are the general eligibility criteria for a patient to receive Lartruvo?

Lartruvo was indicated for adult patients with advanced or metastatic soft tissue sarcoma who had not previously been treated with the chemotherapy agent doxorubicin. Following the results of the later confirmatory trial, the official regulatory status advises against initiating new Lartruvo therapy outside of a clinical research setting.

Q: Is it possible to use Lartruvo if a patient has pre-existing kidney issues?

Official prescribing information indicates that the effects of severe renal (kidney) impairment on Lartruvo exposure are currently designated as unknown. Regulatory documents do not provide specific dose adjustments for patients with mild-to-moderate baseline kidney impairment. The prescribing information indicates that any use in patients with pre-existing kidney issues requires assessment by a healthcare professional.

Q: Why is Lartruvo no longer marketed by the company?

The manufacturer voluntarily withdrew the drug from the global market after consultation with regulatory bodies, including the FDA and EMA. This decision was a direct result of the large Phase 3 ANNOUNCE trial failing to meet its primary objective, which was to confirm the overall survival benefit seen in earlier studies.

Q: Is Lartruvo used only for newly diagnosed patients or for those with recurrent disease?

Lartruvo was indicated for use as a first-line treatment for adult patients with advanced or metastatic soft tissue sarcoma. This means it was intended for those who had not previously been treated with the chemotherapy agent doxorubicin.

Q: What is the main use of Lartruvo, based on official regulatory information?

According to official regulatory documents, Lartruvo was indicated for the treatment of adult patients with advanced or metastatic soft tissue sarcoma (STS). It was always intended to be used in combination with doxorubicin as part of a therapeutic regimen.

Q: How does Lartruvo differ from traditional chemotherapy drugs?

Lartruvo is classified as a targeted therapy and a monoclonal antibody. Unlike traditional chemotherapy, which broadly targets all rapidly dividing cells, Lartruvo works by selectively blocking a specific protein receptor, PDGFR-alpha, to disrupt growth signals in tumor cells.

Q: Are there any severe or long-term side effects associated with Lartruvo use?

The regulatory safety profile lists several severe risks, including serious infusion-related reactions (IRRs) such as low blood pressure and anaphylaxis, and the risk of harm to a fetus (embryo-fetal toxicity). Official assessments did not report the finding of new safety concerns during the confirmatory trial. However, long-term effects beyond the typical duration of clinical follow-up are not explicitly detailed in the labeling.

Q: Can Lartruvo affect a person’s ability to drive or operate machinery?

Official documents do not contain an explicit warning regarding driving or operating machinery. However, common side effects of Lartruvo include fatigue, nausea, and dizziness. The presence of these effects may necessitate caution when performing activities that require concentration.

Q: Is Lartruvo treatment allowed for people with existing heart problems?

Because Lartruvo is given with doxorubicin, the risk of Cardiac Toxicity (heart damage) associated with doxorubicin must be considered. The official prescribing information indicates that this risk requires consideration by a physician when assessing patients with pre-existing heart problems.

Q: Is Lartruvo used for other types of cancer besides soft tissue sarcoma?

The drug’s regulatory authorization was specifically for soft tissue sarcoma. While its mechanism has been studied in other settings, its use outside of this specific cancer type is not supported by the authorized regulatory indication.

Q: Is Lartruvo still available in countries outside of the US?

No. Following the disappointing results of the confirmatory Phase 3 trial, the manufacturer made the decision to withdraw Lartruvo from global markets, including the United States and Europe.

Q: Can older patients generally receive Lartruvo treatment?

The treatment is authorized for adults (18 years and older). Official information indicates that clinical studies did not include sufficient numbers of patients aged 65 years and older to determine if their response to the drug is different from that of younger adults.

Q: What is the withdrawal status of Lartruvo in the European Union (EMA)?

The European Medicines Agency (EMA) recommended and finalized the revocation (withdrawal) of the marketing authorization for Lartruvo. This action was taken based on the results of the ANNOUNCE study, which failed to confirm the clinical benefit.

Q: How is Lartruvo different from general immunotherapy drugs?

Lartruvo is a monoclonal antibody that acts as a targeted therapy by directly blocking a specific growth receptor (PDGFR-alpha) on cells. This is a different approach than most currently available immunotherapy drugs, which generally work by activating or modifying the body's overall immune response to target cancer.

Q: Are there specific lab tests needed before each Lartruvo treatment?

Because Lartruvo is associated with adverse reactions like neutropenia (low white blood cells), the prescribing information indicates that dose adjustments or delays may be necessary. Regulatory information suggests that monitoring is necessary; specific lab tests, such as blood cell counts, are commonly ordered.

Q: Is Lartruvo treatment reported to be painful?

Official safety profiles list musculoskeletal pain (muscle and bone pain) as a very common adverse reaction, affecting a significant number of patients in clinical trials. While this refers to overall pain, pain at the infusion site itself is not explicitly listed as a common reaction.

Q: Can Lartruvo cause changes in blood pressure or heart rhythm?

Hypotension (low blood pressure) is listed as a potential symptom of an infusion-related reaction that can occur during or after administration. Changes in heart rhythm are not explicitly listed as a common or severe adverse effect of Lartruvo alone in the prescribing information.

Q: How does Lartruvo generally affect the immune system?

The most common effects documented on the body's defense system are blood and lymphatic disorders. Official safety information lists low levels of certain white blood cells, specifically neutropenia and lymphopenia, as very common side effects associated with the treatment.

Q: Does Lartruvo treatment require a hospital stay, or is it typically outpatient?

The administration protocol describes Lartruvo as a 60-minute intravenous infusion given on a set weekly schedule. This type of infusion protocol is highly typical of procedures performed in an outpatient setting, such as an infusion center or clinic.

Q: What happens to the drug after it's infused into the body?

Lartruvo is a large-molecule monoclonal antibody designed to target the PDGFR-alpha receptor. Once infused, it travels through the bloodstream to bind to its target. Because it is a protein, it is cleared from the body primarily through a natural process called catabolism (the breaking down of proteins).

Official Storage and Disposal Requirements for Lartruvo

Item	Requirement Statement
Unopened Vial Storage	Store in a refrigerator (2 C to 8 C). Keep the vial in the outer carton to protect from light. Do not freeze.
Diluted Solution Stability	The prepared solution must be stored for up to 24 hours under refrigeration (2 C to 8 C) and for an additional 4–8 hours at room temperature (below 25 C). Storage times include the infusion duration.
Handling Constraints	Do not shake the vial or the diluted solution. Solution preparation must utilize aseptic technique. Contents must be inspected for particulate matter or discoloration prior to use.
Disposal Instructions	The vial and any unused portion of the product must be discarded. Disposal of unused medicinal product and waste material must be in accordance with local requirements for pharmaceutical waste.